AHA urged the House Energy and Commerce Committee to consider including in its draft legislation to address drug shortages legislative proposals that would support drug manufacturers and protect the supply chain for essential medications without limiting patient access to 340B drugs. 
 
“The AHA shares the committee’s concern about ensuring an adequate drug supply. Our member hospitals and health systems rely on drug therapies to care for their patients,” the association wrote. “In many cases, access to these critical drugs is in peril, jeopardizing patient health. Hospitals and health systems are most concerned about preserving consistent supply of and access to source generics and other generics, which drug manufacturers may believe lack sufficient business incentive to maintain. While the AHA believes shoring up the drug supply chain is of great importance, accomplishing this goal should not come at the cost of patient care. Reducing access to the 340B Drug Pricing Program would directly impact hospitals’ ability to offer a wide range of health care services to some of the nation’s most vulnerable populations.” 

Related News Articles

Headline
The Department of Health and Human Services said its decision to prevent drug companies from implementing a 340B rebate model “was within its statutory…
Headline
The AHA this week filed a number of friend-of-the-court briefs in cases before the U.S. District Court for the District of Columbia, urging the court to uphold…
Headline
The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. Court of Appeals for the 4th Circuit, urging the court to affirm a decision by the U.S. District…
Headline
The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. District Court for the District of Columbia, urging the court to uphold the Health Resources…
Headline
AHA President and CEO Rick Pollack joined AHA’s Chad Golder, senior vice president and general counsel, Travis Robey, vice president of political affairs,…
Headline
The Health Resources and Services Administration last week directed Sanofi to cease implementation of its 340B rebate proposal immediately and to inform HRSA…